Gout in the era of multimorbidity: pathogenesis, systemic comorbidities, and evolving therapeutic strategies

Read full text Summarise with VIRAT
Authors: Phillip J Kim, Jihun Kang, J. Yu, Geun-Tae Kim, Yunkyung Kim
Cited by: 0
References: 87

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Gout is the most prevalent inflammatory arthritis worldwide and represents a growing global health burden. It arises from hyperuricemia resulting from disordered purine metabolism, leading to monosodium urate (MSU) crystal deposition and recurrent inflammatory arthritis. Although hyperuricemia is the principal risk factor, genetic susceptibility, impaired urate transport, and emerging factors such as the gut microbiota also contribute to disease development. Acute flares are mediated by MSU crystal-induced activation of the NLRP3 inflammasome and subsequent interleukin-1β production, whereas chronic inflammation results in tophus formation and structural joint damage. Gout is closely associated with metabolic syndrome, chronic kidney disease, and cardiovascular disease, which contribute to persistently elevated mortality. Although advances in imaging and pharmacologic therapy have improved diagnosis and management, the real-world use of urate-lowering therapy remains suboptimal. Further research and sustained efforts by healthcare professionals are needed to improve long-term disease control.

Fields of Study & Subjects

Gout Hyperuricemia Uric Acid Inflammasome and immune disorders Drug-Induced Adverse Reactions

Publication details

Journal / source
Kosin Medical Journal
Volume
41
Issue
1
Pages
26–36
Publication date
31 March 2026
Language
EN